AI assistant
Sending…
Lineage Cell Therapeutics Inc. — Proxy Solicitation & Information Statement 2017
May 3, 2017
6895_rns_2017-05-03_136bcf8a-bb00-456d-b461-24001d05b242.htm
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
_________ false
| ������� ���� | 2 380 |
| .BIOTIME, INC | |
| Corporation no: 876343 | 10834 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C002 ( Public ) | Reported via MAGNA: | 03/05/2017 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2017-02-036652 | Time of broadcast: 09:24 09:20:20 |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
| Attached hereto is a report on SCHEDULE 14A ����� ������ ���� ����� ����� ��� ������ ���� 29 �����, 2017 |
| SCHEDULE_14A_030517_isa.pdf |
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: -1 | Date of revision of form structure: 30/04/2017 |
| Address: HARBOR BAY PARKWAY 1301 , ALAMEDA 94502 CALIFORNIA , U.S.A Tel: 5105213390 , Fax: 5105213389 | |
| E-mail address: [email protected] Company site: biotimeinc.com | |
| Previous names of reporting entity: | |
| Name of the Signatory: Gerzi Ilan Position of Signatory in the reporting corporation: Attorney/Legal Counsel Name of Employer Company: PEARL COHEN ZEDEK LATZER BARATZ | |
| Address: Harbor Bay Parkway 1301 , Alameda 94502 Telephone: 510-5213390 Facsimile: 510-5213389 E-mail: [email protected] 1 | |
| U.S.A |
More from Lineage Cell Therapeutics Inc.
Report Publication Announcement
2026
May 13
Interim / Quarterly Report
2026
May 13
Earnings Release
2026
May 13
Report Publication Announcement
2026
May 13
Report Publication Announcement
2026
May 13
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 4